AI in Pharma 2026: From Insight to Execution in Clinical Trials
White paper
Clinical
Executive Summary
Artificial intelligence (AI) has crossed a threshold in clinical development. Since 2024, AI has moved decisively from pilot projects and point experiments into embedded use across trial planning, execution, and oversight. Sponsors are no longer asking whether AI works, but where it delivers repeatable value and how to scale it responsibly across portfolios.
In 2026, AI is actively being used to:
- Reduce protocol amendments by benchmarking eligibility criteria and endpoints against historically successful trials
- Compress feasibility timelines by weeks through automated cross‑trial and cross‑market comparisons
- Improve enrollment rates by identifying viable patient cohorts earlier and aligning site selection with real‑world performance data
- Support more consistent regulatory and operational decision‑making through curated, auditable data foundations
What has changed most is not the technology itself, but how it is operationalized. Sponsors that are seeing sustained impact share three characteristics: trusted data with transparent provenance, AI embedded directly into trial workflows, and governance designed to enable scale rather than restrict innovation.
This paper focuses on how AI is being used today: what makes it work in practice, and what sponsors should do next.
Get full access now
FAQ
How is AI transforming clinical trials in the pharmaceutical industry?
AI is reshaping clinical trials by accelerating processes such as patient recruitment, site selection, and protocol optimization. It enables predictive and prescriptive analytics, helping sponsors forecast timelines, identify risks early, and design more efficient, patient-centric trials. These capabilities reduce costs and improve success rates.
What are the main benefits of using AI in pharmaceutical R&D?
AI-driven systems significantly reduce drug discovery timelines — from four to five years to as little as six to eight months — by analyzing vast datasets and predicting molecular interactions. AI also enables drug repurposing, personalized therapies, and operational excellence in clinical trials. These improvements enhance efficiency, lower costs, and improve patient outcomes.
What future trends will shape AI in biopharma?
Emerging trends include the integration of digital twins, edge AI, and quantum AI into clinical workflows. Digital twins simulate patient profiles to optimize treatment strategies, while edge AI enables real-time monitoring via wearables for decentralized trials. Quantum AI is being piloted for complex tasks like protein folding and toxicology prediction. These innovations promise faster, more personalized, and secure drug development.
Related products
Protocol SmartDesign
Get a head start on your primary endpoints and I/E criteria
Cohort SmartBuilder
Powered by real-world data, Cohort SmartBuilder shows how eligibility criteria affect patient availability and ensures protocols are built to recruit from the start.
TrialScope Disclose
Manage the complexity of clinical trial disclosure and the risk of noncompliance by automating data entry and reporting to registries
